Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02069080 : Imaging CXCR4 Expression in Subjects With Cancer Using 64 Cu-Plerixafor
PhasePhase 0
AgesMin: 18 Years Max: N/A
Eligibility
- INCLUSION CRITERIA:

Screening Phase

Subjects (greater than or equal to18 years of age) with cancer; at least 1 detectable
solid tumor of greater than or equal to 1.5 cm in diameter found outside of the vertebral
bodies, liver, gallbladder, kidney, and bladder; and, with the exception of adrenocortical
carcinoma, preexisting tumor sample(s) of the cancer obtained since the first detection of
the current occurrence/recurrence of disease are eligible to participate in the screening
portion of the study.

Study Phase

Subjects of reproductive potential are eligible to enter the study if they agree to use 2
forms of contraception 3 weeks prior to the study start and 1 month after the
administration of 64Cu-plerixafor, such as:

- Hormonal contraception.

- Male or female condoms with or without a spermicide.

- Diaphragm or cervical cap with a spermicide.

- Intrauterine device.

Male subjects may commence contraception beginning at the time of infusion of
64Cuplerixafor.

EXCLUSION CRITERIA:

Screening Phase

Subjects who are known to meet Study Phase exclusion criteria during the screening period
may be excluded from entering the Study Phase.

Study Phase

Individuals who meet any of the following criteria are not eligible to participate in the
study:

1. Karnofsky Performance Scale Index (KPSI) < 70.

2. Women who are pregnant or lactating.

3. History of life-threatening cardiac arrhythmia.

4. Absolute neutrophil count < 1000/microliters.

5. Platelet count < 100,000/microliters.

6. Alanine transaminase, aspartate aminotransferase, alkaline phosphatase, or bilirubin
levels greater than or equal to 4 times the upper limits of normal, or a calculated
creatinine clearance rate of less than or equal to 50 mL/min.

7. Treatment with plerixafor or any imaging agent with a radioisotope or labeled
molecule administered < 10 half-lives prior to administration of 64Cu-plerixafor.

8. Research radiation exposure over the past 12 months, which if added to the radiation
exposure in this study, exceeds 5 rem.

9. Allergy to plerixafor.

10. Severe claustrophobia unresponsive to anxiolytics.

11. Weight over 325 pounds.

12. History of any other illness or condition which, in the investigator s opinion, may
substantially increase the risk associated with the subject s participation in the
study, or may compromise the scientific objectives.

Co-Enrollment Guidelines

Co-enrollment in other trials that involve the infusion of radioactive isotopes/molecules
for research purposes or plerixafor is prohibited.
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT02069080      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740